NCT07042295 2026-03-18
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
15 trialsNCT06120140 2026-03-13
COCOON
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05117931 2026-02-17
A Study of Amivantamab in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05498428 2026-02-13
PALOMA-2
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07392658 2026-02-06
AMICUTE
Fondazione Ricerca Traslazionale
Phase 2 Recruiting
NCT05601973 2026-01-21
AMAZE-lung
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT06667076 2026-01-16
COPERNICUS
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT04965090 2025-12-18
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06116682 2025-12-05
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Recruiting
NCT05299125 2025-10-01
AMIGO-1
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05074940 2025-04-10
Amivantamab in Adenoid Cystic Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT06855849 2025-03-04
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
Yonsei University
Phase 2 Not yet recruiting
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT04945733 2024-09-19
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Janssen Pharmaceutical K.K.
Phase 2 Terminated
NCT03767075 2024-04-25
BoB
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting